{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:10:12Z","timestamp":1788174612851,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41571-020-0367-1","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T06:03:43Z","timestamp":1588745023000},"page":"493-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treatment-free remission in patients with chronic myeloid leukaemia"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"367_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343\u20133356 (2000).","journal-title":"Blood"},{"key":"367_CR2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford, S. et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 33, 1835\u20131850 (2019).","journal-title":"Leukemia"},{"key":"367_CR3","unstructured":"Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn (IARC, 2017)."},{"key":"367_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"367_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele, S. et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126, 42\u201349 (2015).","journal-title":"Blood"},{"key":"367_CR6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044\u20131054 (2016).","journal-title":"Leukemia"},{"key":"367_CR7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E. et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J. Clin. Oncol. 34, 2333\u20132340 (2016).","journal-title":"J. Clin. Oncol."},{"key":"367_CR8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton, J. H. et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 17, 612\u2013621 (2016).","journal-title":"Lancet Oncol."},{"key":"367_CR9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Eng. J. Med. 376, 917\u2013927 (2017).","journal-title":"N. Eng. J. Med."},{"key":"367_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman, J. & Gordon, M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk. Lymphoma 47, 1\u20137 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","volume":"337","author":"F Guilhot","year":"1997","unstructured":"Guilhot, F. et al. French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med. 337, 223\u2013229 (1997).","journal-title":"N. Engl. J. Med."},{"key":"367_CR12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994\u20131004 (2003).","journal-title":"N. Engl. J. Med."},{"key":"367_CR13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani, M. et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33, 1173\u20131183 (2019).","journal-title":"Leukemia"},{"key":"367_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28\u201337 (2006).","journal-title":"Blood"},{"key":"367_CR15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423\u20131432 (2003).","journal-title":"N. Engl. J. Med."},{"key":"367_CR16","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"S Branford","year":"2007","unstructured":"Branford, S. et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin. Cancer Res. 13, 7080\u20137085 (2007).","journal-title":"Clin. Cancer Res."},{"key":"367_CR17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford, S. et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20, 1925\u20131930 (2006).","journal-title":"Leukemia"},{"key":"367_CR18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross, N. C. et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29, 999\u20131003 (2015).","journal-title":"Leukemia"},{"key":"367_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann, R. et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J. Clin. Oncol. 32, 415\u2013423 (2014).","journal-title":"J. Clin. Oncol."},{"key":"367_CR20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58\u201360 (2007).","journal-title":"Blood"},{"key":"367_CR21","unstructured":"National Comprehensive Cancer Network. Chronic Myeloid Leukemia www.nccn.org (2017)."},{"key":"367_CR22","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28 (Suppl. 4)","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus, A. et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28 (Suppl. 4), iv41\u2013iv51 (2017).","journal-title":"Ann. Oncol."},{"key":"367_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes, T. P. & Ross, D. M. Moving treatment-free remission into mainstream clinical practice in CML. Blood 128, 17\u201323 (2016).","journal-title":"Blood"},{"key":"367_CR24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"367_CR25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne, G. et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 35, 298\u2013305 (2017).","journal-title":"J. Clin. Oncol."},{"key":"367_CR26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"367_CR27","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","volume":"32","author":"DM Ross","year":"2018","unstructured":"Ross, D. M. et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia 32, 2572\u20132579 (2018).","journal-title":"Leukemia"},{"key":"367_CR28","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini, F. E. et al. Evaluation of residual disease and tki duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin. Cancer Res. 25, 6606\u20136613 (2019).","journal-title":"Clin. Cancer Res."},{"key":"367_CR29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","volume":"24","author":"S Fujisawa","year":"2019","unstructured":"Fujisawa, S. et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int. J. Clin. Oncol. 24, 445\u2013453 (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"367_CR30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot, P. et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J. Clin. Oncol. 32, 424\u2013430 (2014).","journal-title":"J. Clin. Oncol."},{"key":"367_CR31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","volume":"88","author":"SE Lee","year":"2013","unstructured":"Lee, S. E. et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am. J. Hematol. 88, 449\u2013454 (2013).","journal-title":"Am. J. Hematol."},{"key":"367_CR32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori, S. et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am. J. Hematol. 90, 910\u2013914 (2015).","journal-title":"Am. J. Hematol."},{"key":"367_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi, N. et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int. J. Hematol. 107, 185\u2013193 (2018).","journal-title":"Int. J. Hematol."},{"key":"367_CR34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19, 747\u2013757 (2018).","journal-title":"Lancet Oncol."},{"key":"367_CR35","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"RE Clark","year":"2017","unstructured":"Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 4, e310\u2013e316 (2017).","journal-title":"Lancet Haematol."},{"key":"367_CR36","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 6, e375\u2013e383 (2019).","journal-title":"Lancet Haematol."},{"key":"367_CR37","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","volume":"119","author":"S Branford","year":"2012","unstructured":"Branford, S. et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 119, 4264\u20134271 (2012).","journal-title":"Blood"},{"key":"367_CR38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee, S. E. et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101, 717\u2013723 (2016).","journal-title":"Haematologica"},{"key":"367_CR39","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura, S. et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 7, e218\u2013e225 (2020).","journal-title":"Lancet Haematol."},{"key":"367_CR40","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa, J. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2, e528\u2013e535 (2015).","journal-title":"Lancet Haematol."},{"key":"367_CR41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","volume":"18","author":"M Okada","year":"2018","unstructured":"Okada, M. et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin. Lymphoma Myeloma Leuk. 18, 353\u2013360 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"367_CR42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai, T. et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 109, 182\u2013192 (2018).","journal-title":"Cancer Sci."},{"key":"367_CR43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah, N. P. et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk. Lymphoma 61, 650\u2013659 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR44","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129, 846\u2013854 (2017).","journal-title":"Blood"},{"key":"367_CR45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi, N. et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica 103, 1835\u20131842 (2018).","journal-title":"Haematologica"},{"key":"367_CR46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon, F. X. et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann. Intern. Med. 168, 461\u2013470 (2018).","journal-title":"Ann. Intern. Med."},{"key":"367_CR47","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus, A. et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31, 1525\u20131531 (2017).","journal-title":"Leukemia"},{"key":"367_CR48","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross, D. M. et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J. Cancer Res. Clin. Oncol. 144, 945\u2013954 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"367_CR49","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani, M. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108, 1809\u20131820 (2006).","journal-title":"Blood"},{"key":"367_CR50","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041\u20136051 (2009).","journal-title":"J. Clin. Oncol."},{"key":"367_CR51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872\u2013884 (2013).","journal-title":"Blood"},{"key":"367_CR52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich, J. P. et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 16, 1108\u20131135 (2018).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"367_CR53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019000120","volume":"134","author":"N Shanmuganathan","year":"2019","unstructured":"Shanmuganathan, N. et al. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood 134, 85\u201389 (2019).","journal-title":"Blood"},{"key":"367_CR54","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3324\/haematol.2018.189787","volume":"103","author":"IS Pagani","year":"2018","unstructured":"Pagani, I. S. et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica 103, 2026\u20132032 (2018).","journal-title":"Haematologica"},{"key":"367_CR55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi, L. et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am. J. Hematol. 88, 1024\u20131029 (2013).","journal-title":"Am. J. Hematol."},{"key":"367_CR56","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","volume":"28","author":"JM Goldman","year":"2010","unstructured":"Goldman, J. M. et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28, 1888\u20131895 (2010).","journal-title":"J. Clin. Oncol."},{"key":"367_CR57","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.leukres.2009.03.010","volume":"33","author":"A Sekhri","year":"2009","unstructured":"Sekhri, A. et al. Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk. Res. 33, 1291\u20131293 (2009).","journal-title":"Leuk. Res."},{"key":"367_CR58","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000157","volume":"2","author":"A Papalexandri","year":"2018","unstructured":"Papalexandri, A. et al. Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop? HemaSphere 2, e157 (2018).","journal-title":"HemaSphere"},{"key":"367_CR59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2019-124408","volume":"134","author":"D Rea","year":"2019","unstructured":"Rea, D. et al. Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update. Blood 134, 30 (2019).","journal-title":"Blood"},{"key":"367_CR60","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","volume":"55","author":"O Benjamini","year":"2014","unstructured":"Benjamini, O. et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk. Lymphoma 55, 2879\u20132886 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR61","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter, J. et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J. Clin. Oncol. 32, 2821\u20132823 (2014).","journal-title":"J. Clin. Oncol."},{"key":"367_CR62","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah, N. P. et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk. Lymphoma 61, 650\u2013659 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","volume":"187","author":"MG Berger","year":"2019","unstructured":"Berger, M. G. et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br. J. Haematol. 187, 337\u2013346 (2019).","journal-title":"Br. J. Haematol."},{"key":"367_CR64","first-page":"873","volume":"57","author":"S Katagiri","year":"2016","unstructured":"Katagiri, S. et al. Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey. Rinsho Ketsueki 57, 873\u2013876 (2016).","journal-title":"Rinsho Ketsueki"},{"key":"367_CR65","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","volume":"59","author":"LA Villemagne Sanchez","year":"2018","unstructured":"Villemagne Sanchez, L. A. et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk. Lymphoma 59, 406\u2013415 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR66","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","volume":"39","author":"M Breccia","year":"2015","unstructured":"Breccia, M. et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk. Res. 39, 1055\u20131059 (2015).","journal-title":"Leuk. Res."},{"key":"367_CR67","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang, Q., Liu, Z. C., Zhang, S. X. & Gale, R. P. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J. Cancer Res. Clin. Oncol. 142, 1539\u20131547 (2016).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"367_CR68","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes, D. J. et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65, 8912\u20138919 (2005).","journal-title":"Cancer Res."},{"key":"367_CR69","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros, L. et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer 123, 4403\u20134410 (2017).","journal-title":"Cancer"},{"key":"367_CR70","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye, S. M. et al. The effects of imatinib on pregnancy outcome. Blood 111, 5505\u20135508 (2008).","journal-title":"Blood"},{"key":"367_CR71","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes, J. E. et al. The impact of dasatinib on pregnancy outcomes. Am. J. Hematol. 90, 1111\u20131115 (2015).","journal-title":"Am. J. Hematol."},{"key":"367_CR72","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","volume":"36","author":"E Berman","year":"2018","unstructured":"Berman, E., Druker, B. J. & Burwick, R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J. Clin. Oncol. 36, 1250\u20131256 (2018).","journal-title":"J. Clin. Oncol."},{"key":"367_CR73","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1200\/JCO.2018.78.6137","volume":"36","author":"DM Ross","year":"2018","unstructured":"Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. P. & Seymour, J. F. Management of pregnancy in women with chronic myeloid leukemia. J. Clin. Oncol. 36, 2657\u20132658 (2018).","journal-title":"J. Clin. Oncol."},{"key":"367_CR74","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","volume":"102","author":"S Claudiani","year":"2017","unstructured":"Claudiani, S. et al. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102, e297\u2013e299 (2017).","journal-title":"Haematologica"},{"key":"367_CR75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal, J. E. et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63, 789\u2013799 (1984).","journal-title":"Blood"},{"key":"367_CR76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann, M. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30, 48\u201356 (2016).","journal-title":"Leukemia"},{"key":"367_CR77","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","volume":"125","author":"M D\u2019Adda","year":"2019","unstructured":"D\u2019Adda, M. et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 125, 1674\u20131682 (2019).","journal-title":"Cancer"},{"key":"367_CR78","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719\u20131724 (2010).","journal-title":"Leukemia"},{"key":"367_CR79","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2010.174","volume":"24","author":"J Score","year":"2010","unstructured":"Score, J. et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia 24, 1742\u20131750 (2010).","journal-title":"Leukemia"},{"key":"367_CR80","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","volume":"157","author":"K Ohyashiki","year":"2012","unstructured":"Ohyashiki, K. et al. Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br. J. Haematol. 157, 254\u2013256 (2012).","journal-title":"Br. J. Haematol."},{"key":"367_CR81","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander, M. et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31, 1108\u20131116 (2017).","journal-title":"Leukemia"},{"key":"367_CR82","first-page":"e56","volume":"186","author":"DM Ross","year":"2019","unstructured":"Ross, D. M. et al. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. Br. J. Haematol. 186, e56\u2013e60 (2019).","journal-title":"Br. J. Haematol."},{"key":"367_CR83","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2017.348","volume":"32","author":"C Schutz","year":"2018","unstructured":"Schutz, C. et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 32, 1054 (2018).","journal-title":"Leukemia"},{"key":"367_CR84","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3324\/haematol.2018.189787","volume":"103","author":"IS Pagani","year":"2018","unstructured":"Pagani, I. S. et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica 103, 2026\u20132032 (2018).","journal-title":"Haematologica"},{"key":"367_CR85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2018.00194","volume":"8","author":"M Bocchia","year":"2018","unstructured":"Bocchia, M. et al. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front. Oncol. 8, 194 (2018).","journal-title":"Front. Oncol."},{"key":"367_CR86","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","volume":"7","author":"JC Chomel","year":"2016","unstructured":"Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 7, 35293\u201335301 (2016).","journal-title":"Oncotarget"},{"key":"367_CR87","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand, M. et al. Chronic myeloid leukemia stem cells. Leukemia 33, 1543\u20131556 (2019).","journal-title":"Leukemia"},{"key":"367_CR88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","volume":"25","author":"DM Ross","year":"2011","unstructured":"Ross, D. M., Hughes, T. P. & Melo, J. V. Do we have to kill the last CML cell? Leukemia 25, 193\u2013200 (2011).","journal-title":"Leukemia"},{"key":"367_CR89","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","volume":"123","author":"CY Cheah","year":"2014","unstructured":"Cheah, C. Y. et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 123, 3574\u20133577 (2014).","journal-title":"Blood"},{"key":"367_CR90","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","volume":"92","author":"F Legrand","year":"2013","unstructured":"Legrand, F. et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine 92, e1\u2013e9 (2013).","journal-title":"Medicine"},{"key":"367_CR91","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1002\/ajh.24422","volume":"91","author":"M Cerrano","year":"2016","unstructured":"Cerrano, M. et al. Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm. Am. J. Hematol. 91, E353 (2016).","journal-title":"Am. J. Hematol."},{"key":"367_CR92","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/10428194.2015.1065983","volume":"57","author":"G Helbig","year":"2016","unstructured":"Helbig, G., Soja, A., Swiderska, A., Hus, M. & Kyrcz-Krzemien, S. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leuk. Lymphoma 57, 708\u2013710 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"367_CR93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14748","volume":"182","author":"A Bidet","year":"2018","unstructured":"Bidet, A. et al. Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation. Br. J. Haematol. 182, 148\u2013152 (2018).","journal-title":"Br. J. Haematol."},{"key":"367_CR94","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon, C. M. et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 9, 1050\u20131063 (2019).","journal-title":"Cancer Discov."},{"key":"367_CR95","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"367_CR96","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen, Y. J. L. et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann. Oncol. 30, 1154\u20131161 (2019).","journal-title":"Ann. Oncol."},{"key":"367_CR97","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"AC Tan","year":"2018","unstructured":"Tan, A. C. et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann. Oncol. 29, 2115\u20132120 (2018).","journal-title":"Ann. Oncol."},{"key":"367_CR98","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet, T. et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J. Transl Med. 17, 303 (2019).","journal-title":"J. Transl Med."},{"key":"367_CR99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahlen","year":"2016","unstructured":"Dahlen, T. et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann. Intern. Med. 165, 161\u2013166 (2016).","journal-title":"Ann. Intern. Med."},{"key":"367_CR100","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz, M. et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121, 3894\u20133904 (2015).","journal-title":"Cancer"},{"key":"367_CR101","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","volume":"6","author":"YT Shih","year":"2019","unstructured":"Shih, Y. T., Cortes, J. E. & Kantarjian, H. M. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 6, e398\u2013e408 (2019).","journal-title":"Lancet Haematol."},{"key":"367_CR102","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0038-1661257","volume":"53","author":"EA Loeliger","year":"1985","unstructured":"Loeliger, E. A., van den Besselaar, A. M. & Lewis, S. M. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb. Haemost. 53, 148\u2013154 (1985).","journal-title":"Thromb. Haemost."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0367-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:43:55Z","timestamp":1684604635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-0367-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"1 April 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M.R. receives research funding and honoraria from BMS and Novartis. T.P.H. receives research funding and honoraria from BMS and Novartis and is a member of the advisory board for BMS, Incyte and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}